Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)
ID: 359854Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Private Institutions of Higher Education

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359854
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Pharmacokinetics Resource Laboratory (PK Laboratory) to support the Experimental Therapeutics Clinical Trials Network (ETCTN). This initiative aims to solicit applications from private institutions of higher education to maintain or establish a laboratory that will facilitate biospecimen collections and analyze pharmacokinetic endpoints, drug-drug interactions, and other critical factors in clinical trials involving NCI Investigational New Drug (IND) agents. The PK Laboratory is essential for advancing the clinical development of these agents and will require a multidisciplinary approach, including technical services, scientific leadership, and biospecimen management. The estimated total program funding is $850,000, with one award anticipated, and the NOFO is expected to be published in Summer 2025, with applications due in Fall 2025. For further inquiries, interested parties can contact Dr. Lori A. Henderson at NCIETCTNRFA@mail.nih.gov or by phone at 240-276-5930.

    Point(s) of Contact
    Lori A. Henderson, Ph.D. National Cancer Institute (NCI)
    (240) 276-5930
    NCIETCTNRFA@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (LAOs), with an estimated total program funding of $12 million. This initiative aims to solicit applications from private institutions of higher education to establish or maintain LAOs that will design, conduct, and analyze early phase clinical trials involving investigational agents under the regulatory sponsorship of the NIH's Division of Cancer Treatment and Diagnosis. The ETCTN LAOs will play a critical role in overseeing scientific, programmatic, financial, and administrative aspects of the trials, while also providing mentorship to early-career investigators. The NOFO is expected to be published in Summer 2025, with applications due in Fall 2025. For further inquiries, interested parties can contact Lori A. Henderson, Ph.D., at NCIETCTNRFA@mail.nih.gov or by phone at 240-276-5930.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network, specifically targeting Network Lead Academic Participating Sites through a cooperative agreement. The primary objective is to provide scientific leadership in developing and conducting multi-center clinical trials for various cancer treatments, contributing to substantial patient accrual across the NCTN. This initiative is crucial for advancing clinical research and improving treatment options for diverse patient populations affected by cancer. The estimated total program funding is $35,100,000, with an award ceiling of $1,700,000 and approximately 35 awards expected. Interested applicants should prepare for the anticipated application due date in late February 2025, following the NOFO publication in Fall 2024.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Institutional Network Award aimed at promoting research training in kidney, urologic, and hematologic fields. This initiative seeks to support institutions in developing a robust network to engage and train the next generation of researchers through innovative outreach and career development activities, with each institution eligible to apply for a single award to support at least five trainee slots. The total estimated funding for this program is $4 million, with an award ceiling of $2.1 million, and the NIH anticipates making approximately eight awards. Interested applicants can reach out to Dr. Tracy Rankin at rankint@niddk.nih.gov or (301) 594-4748 for further information, with the estimated synopsis post date set for July 5, 2025, and applications expected to be solicited by October 5, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for a single-source grant aimed at establishing the NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network. This initiative seeks to partner with private institutions of higher education to conduct large-scale, multi-site clinical trials, focusing on late-phase treatment trials and advanced imaging across various cancer types, while ensuring regulatory oversight in Canada. The funding, estimated at $3.8 million, is intended to support the NCTN's efforts to enhance clinical research for diverse patient populations, with the application due in late February 2025 and the award anticipated by March 1, 2026. Interested applicants should prepare their proposals in advance of the expected NOFO publication in Fall 2024.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-issue of PAR-21-339 - Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25), with a focus on educational activities that enhance research experiences in clinical and translational science. This initiative aims to support recipients of Clinical and Translational Science Awards (CTSA) by providing exposure to the scientific and operational principles of the translational process, covering areas such as pre-clinical research, clinical research, clinical implementation, and public health. The anticipated funding amount for this grant is up to $100,000, with the NOFO expected to be published in Summer 2024 and applications due by January 27, 2025. For further details, potential applicants are encouraged to prepare their proposals in advance of the expected award date on December 16, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.